A unique case of sepsis-triggered reverse Takotsubo cardiomyopathy resulting in cardiogenic shock
Abstract
Reverse Takotsubo syndrome (rTTS) is an acute cardiomyopathy characterized by prominent dysfunction in the basilar and mid-ventricular segments with apical hyperkinesis, often triggered by excessive stress hormone release. Sepsis can exacerbate this process. We present a unique case of a 27-year-old male with no chronic illnesses who developed sepsis-triggered rTTS resulting in cardiogenic shock. The initial presentation included nausea, vomiting, tachypnea, and fluctuating blood pressure. Laboratory findings revealed elevated cardiac and inflammatory markers, metabolic acidosis, and bacteremia caused by Staphylococcus aureus. Echocardiography showed an initial left ventricular ejection fraction (LVEF) of 45% with basal mid-ventricular hypokinesia and apical hyperkinesis, characteristic of rTTS. Coronary angiography excluded obstructive coronary artery disease. The patient developed cardiogenic shock (SCAI Stage D) requiring vasopressors and mechanical circulatory support with an Impella CP® device. Complications included acute kidney injury requiring renal replacement therapy and posterior reversible encephalopathy syndrome (PRES). With targeted antimicrobial therapy and supportive care, the patient's LVEF improved to 60-65%, and he made a significant clinical recovery. This case highlights the importance of recognizing sepsis as a trigger for rTTS and the potential for full recovery with prompt, aggressive management, including mechanical circulatory support.
##plugins.themes.bootstrap3.article.details##
Reverse Takotsubo Syndrome, Sepsis, Cardiogenic Shock, Mechanical Circulatory Support, Myocardial Injury
2. Singh K, Carson K, Shah R, et al. Meta-analysis of clinical correlates of acute mortality in takotsubo cardiomyopathy. Am J Cardiol. 2014 Apr 15;113(8):1420-8. doi: 10.1016/j.amjcard.2014.01.419. PMID: 24685327.
3. Lyon AR, Bossone E, Schneider B, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016 Jan;18(1):8-27. doi: 10.1002/ejhf.424. PMID: 26548803.
4. Muller-Werdan U, Buerke M, Ebelt H, et al. Septic cardiomyopathy - A not yet discovered cardiomyopathy? Exp Clin Cardiol. 2006 Fall;11(3):226-36. PMID: 18651035; PMCID: PMC2276158.
5. Sato H. Takotsubo-type cardiomyopathy due to multivessel spasm. In: Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure. Tokyo: Kagaku Hyoronsha; 1990. p. 56–64.
6. Ghallab M, Mohamed I, Haseeb Ul Rasool M, et al. Reverse Takotsubo Cardiomyopathy in a Critically Ill Patient in the ICU: A Case Report With Literature Review. Cureus. 2023 Mar 4;15(3):e35752. doi: 10.7759/cureus.35752. PMID: 37020491; PMCID: PMC10069287.
7. Scantlebury DC, Prasad A. Diagnosis of Takotsubo cardiomyopathy. Circ J. 2014;78(9):2129-39. doi: 10.1253/circj.cj-14-0859. PMID: 25131525.
8. Almendro-Delia M, Núñez-Gil IJ, Lobo M, et al. Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome: Results From the RETAKO Registry. JACC Heart Fail. 2018 Nov;6(11):928-936. doi: 10.1016/j.jchf.2018.05.015. PMID: 30316938.
9. Nayak R, Chiu S, Schweis F, Shen AYJ, Lee MS. Cardiogenic Shock and Respiratory Failure Complicating Takotsubo Syndrome. J Invasive Cardiol. 2022 Apr;34(4):E274-E280. doi: 10.25270/jic/21.00086. PMID: 35286276.
10. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. J Am Coll Cardiol. 2022 Mar 8;79(9):933-946. doi: 10.1016/j.jacc.2022.01.018. PMID: 35115207.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.
https://orcid.org/0000-0002-3432-3639